Zineb Hamilou

965 total citations · 1 hit paper
18 papers, 652 citations indexed

About

Zineb Hamilou is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Zineb Hamilou has authored 18 papers receiving a total of 652 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 6 papers in Surgery and 6 papers in Oncology. Recurrent topics in Zineb Hamilou's work include Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Urinary and Genital Oncology Studies (4 papers). Zineb Hamilou is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Urinary and Genital Oncology Studies (4 papers). Zineb Hamilou collaborates with scholars based in Canada, France and United States. Zineb Hamilou's co-authors include Jay P. Patel, Parva Bhatt, Lucy A. Godley, Ross L. Levine, María E. Figueroa, Mithat Gönen, Lambert Busque, Ari Melnick, Aparna Vasanthakumar and Christopher E. Mason and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and The Oncologist.

In The Last Decade

Zineb Hamilou

14 papers receiving 647 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

2012 577 citations Lambert Busque, Jay P. Patel et al. Nature Genetics profile →

Peers

Countries citing papers authored by Zineb Hamilou

Since Specialization

Citations

This map shows the geographic impact of Zineb Hamilou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zineb Hamilou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zineb Hamilou more than expected).

Fields of papers citing papers by Zineb Hamilou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zineb Hamilou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zineb Hamilou. The network helps show where Zineb Hamilou may publish in the future.

Co-authorship network of co-authors of Zineb Hamilou

This figure shows the co-authorship network connecting the top 25 collaborators of Zineb Hamilou. A scholar is included among the top collaborators of Zineb Hamilou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zineb Hamilou. Zineb Hamilou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma 2025 ·The Oncologist ·(unknown), Zineb Hamilou, Sunita Ghosh, Daniel Yick Chin Heng, Lori Wood, Naveen S. Basappa, Christian Kollmannsberger, Jeffrey Graham, Bimal Bhindi, Antonio Finelli, Georg A. Bjarnason, Dominick Bossé, Frédéric Pouliot, Vincent Castonguay, Rodney H. Breau, Ramy Saleh, Eric Winquist, Aly‐Khan A. Lalani, Denis Soulières	1
2	Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC). 2024 ·Journal of Clinical Oncology ·Frédéric Pouliot, Fred Saad, Étienne Rousseau, Patrick O. Richard, (unknown), Stephan Probst, Éric Lévesque, Vincent Castonguay, Nicolas Marcoux, Daniel Juneau, Michele Lodde, Jean‐Baptiste Lattouf, François-Alexandre Buteau, Zineb Hamilou, Michel Pavic, (unknown), Guillaume F. Bouvet, Amélie Têtu, Brigitte Guérin, Jean‐Mathieu Beauregard	5
3	Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study. 2023 ·Journal of Clinical Oncology ·Edmond M. Kwan, Moira Rushton, (unknown), Sébastien J. Hotte, Som D. Mukherjee, Michael Ong, Michael Kolinsky, Zineb Hamilou, Eric Winquist, Cristiano Ferrario, Robyn Jane Macfarlane, Fred Saad, Muhammad Salim, Di Jiang, Dongsheng Tu, (unknown), Matti Annala, Lesley Seymour, Kim N., Alexander W. Wyatt	4
4	Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study. 2023 ·Journal of Clinical Oncology ·Frédéric Pouliot, Fred Saad, Patrick O. Richard, Stephan Probst, Étienne Rousseau, Éric Lévesque, Vincent Castonguay, Nicolas Marcoux, Michele Lodde, Jean‐Baptiste Lattouf, François-Alexandre Buteau, Daniel Juneau, Zineb Hamilou, Michel Pavic, (unknown), (unknown), Guillaume F. Bouvet, Amélie Têtu, Brigitte Guérin, Jean‐Mathieu Beauregard, (unknown)	1
5	Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada 2023 ·Journal of Pharmacy & Pharmaceutical Sciences ·Karen Gambaro, (unknown), (unknown), Arif Awan, (unknown), Mahmoud Abdelsalam, Ève St‐Hilaire, F. Vincent, Julie Carrier, Helen Mackay, Louise Provencher, Dominique K. Boudreau, Zineb Hamilou, Fred Saad, Cristiano Ferrario, Gerald Batist, Maud Marques	0
6	A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer 2022 ·Canadian Urological Association Journal ·(unknown), Fred Saad, Maroie Barkati, Jean‐Baptiste Lattouf, Paul Perrotte, Pierre I. Karakiewicz, Denis Soulières, Normand Blais, Zineb Hamilou, Daniel Juneau, (unknown), Daniel Taussky, Guila Delouya	4
7	Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments? 2021 ·Therapeutic Advances in Medical Oncology ·Anna Patrikidou, Thomas Zilli, Giulia Baciarello, (unknown), Zineb Hamilou, Karim Fizazi	5
8	Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context 2021 ·Canadian Urological Association Journal ·Michael Kolinsky, (unknown), Edmond M. Kwan, Sébastien J. Hotte, Zineb Hamilou, Steven Yip, Kim N., Alexander W. Wyatt, Fred Saad	3
9	A drug safety evaluation of enzalutamide to treat advanced prostate cancer 2021 ·Expert Opinion on Drug Safety ·Fred Saad, Zineb Hamilou, Jean‐Baptiste Lattouf	4
10	The evolving options in metastatic castration-sensitive prostate cancer 2020 ·Current Opinion in Supportive and Palliative Care ·Zineb Hamilou	0
11	Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada 2019 ·Canadian Urological Association Journal ·Zineb Hamilou, Scott North, Christina Canil, Lori Wood, Sébastien J. Hotte, Srikala S. Sridhar, Denis Soulières, Mathieu Latour, Daniel Taussky, Wassim Kassouf, Normand Blais	26
12	Comprehensive and epidemiological characterization of urachal adenocarcinoma: A pan-Canadian collaboration. 2019 ·Journal of Clinical Oncology ·Wiam Belkaïd, Zineb Hamilou, Denis Soulières, Christina M. Canil, Paweł Zalewski, Daniel Yick Chin Heng, (unknown), (unknown), Bertrand Routy, Normand Blais	0
13	Treatment of hormone-naïve metastatic prostate cancer 2018 ·Current Opinion in Supportive and Palliative Care ·Zineb Hamilou, Fred Saad, Karim Fizazi	2
14	Durvalumab in urothelial cancers 2018 ·Expert Review of Anticancer Therapy ·Pernelle Lavaud, Zineb Hamilou, Yohann Loriot, Christophe Massard	8
15	Treatment of Castration-naive Metastatic Prostate Cancer 2017 ·European Urology Focus ·Zineb Hamilou, Giulia Baciarello, Karim Fizazi	2
16	Atezolizumab in Urothelial Bladder Carcinoma 2017 ·Future Oncology ·Zineb Hamilou, Pernelle Lavaud, Yohann Loriot	10
17	Early replacement of CT scanning by abdomino-pelvic ultrasound as a safe alternative in the follow-up of patients with germ cell tumors. 2017 ·Journal of Clinical Oncology ·Giulia Baciarello, Zineb Hamilou, (unknown), (unknown), Laurence Albigès, Yohann Loriot, Christophe Massard, Mario Di Palma, Bernard Escudier, Karim Fizazi	0
18	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis breakdown → 2012 ·Nature Genetics ·Lambert Busque, Jay P. Patel, María E. Figueroa, Aparna Vasanthakumar, Sylvie Provost, Zineb Hamilou, Luigina Mollica, Juan Li, Agnès Viale, Adriana Heguy, (unknown), Nicholas D. Socci, Parva Bhatt, Mithat Gönen, Christopher E. Mason, Ari Melnick, Lucy A. Godley, Cameron Brennan, Omar Abdel‐Wahab, Ross L. Levine	577

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact